A bill called the “Improving Access to Affordable Prescription Drugs Act” (S771) was introduced on March 29, 2017, by Senator Al Franken of Minnesota and 15 co-sponsoring Democrats to improve the Affordable Care Act by bringing down the skyrocketing prices of prescription drugs, which the Senators state is one of the main reasons why healthcare costs are rising.
The bill seeks to tackle prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition. A companion bill [H 1776] with the same name was introduced in the House of Representatives by Rep. Jan Schakowsky of Illinois and 4 co-sponsoring Democrats.
The bill notes “much of the biomedical innovation motivating new drug discovery is supported by the National Institutes of Health (NIH) and other federal programs.” To better understand how research and development costs, manufacturing and marketing costs, acquisitions, federal investments, revenues and sales, and other factors influence drug prices, the bill requires drug makers to disclose this information, by product, to the secretary of the HHS, who in turn will make it publicly available.
The bill will examine how patient assistance programs affect drug prices and “the extent to which drug makers are using independent charity assistance programs to drive up profits.” It also allows the secretary of HHS to negotiate with drug companies to lower prescription drug prices for Medicare, which it is not currently allowed to do. HHS can only negotiate drug prices for Medicaid and the Department of Veterans Affairs.
In addition, the bill will do the following:
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.